Login to Your Account

'Gilenya' be more specific? Receptos can: Phase II with S1P1 portends success in MS

By Randy Osborne
Staff Writer

Tuesday, June 10, 2014
Half of all multiple sclerosis (MS) patients in the nearly $16 billion (and growing) market will be taking oral drugs two years from now, and they'll cycle from one to another, just as they've done in the past with other therapies, predicted Receptos Inc. CEO Faheem Hasnain.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription